Skip to main content

Table 2 Clinical significance of exosomal miRNAs in HCC

From: Exosomal miRNAs in hepatocellular carcinoma development and clinical responses

Clinical significance Exosomal miRNAs Source Expression in HCC Clinical relevance Ref.
Detection and diagnosis miR-665 Serum Up Higher in HCC than the healthy and associated with HCC progression [32]
miR-18a, miR-221, miR-222, miR-224 Serum Up Distinguishes HCC from CHB or LC [34]
miR-21 Serum Up Higher in HCC than in CHB and in healthy volunteers [35]
miR-101, miR-106b, miR-122, miR-195 Serum Down Distinguishes HCC from CHB or LC [34]
miR-9-3p Serum Down Lower levels in HCC than in healthy donors [36]
Detection, prognosis and recurrence miR-638 Serum Down Predicts poor prognosis in HCC patients [33]
miR-125b Serum Down Lower levels of exosomal miR-125b correlated with shorter time to recurrence and reduced overall survival [38]
miR-718 Serum Down Poor prognosis and high rate of recurrence after liver transplantation [37]
Potential treatment miR-122 Cells Down Renders HCC cells more sensitive to chemotherapeutic agents and improves the anti-tumor effect of sorafenib on HCC in vivo [43]
miR-335-5p Cells Down Inhibits recipient cell proliferation and tumor growth in vivo [18]
  1. Exosomal miRNAs as biomarkers can be used for detection, diagnosis, prognosis, and recurrence and can be a potential treatment of HCC
  2. HCC hepatocellular carcinoma, CHB chronic hepatitis, LC liver cirrhosis